Testicular Cancer Likely to Be Cured, Even When It Recurs
Oct. 3, 2000 -- Lance Armstrong only brought a bronze medal home from the Sydney Olympics. The reason for the word "only" is because Armstrong, one of the world's premiere cyclists, is used to winning. Nowhere was this more evident than in the way he defeated his biggest challenge, an advanced case of testicular cancer, where winning was the only option.
Armstrong is not alone in his victory, though. Even though the treatment may be arduous, winning against testicular cancer is becoming more common, both among world-class athletes and the guy on the street.
"My own experience with testicular cancer parallels Lance's," says Chris Brewer, spokesperson for the Lance Armstrong Foundation and founder of the Testicular Cancer Resource Center. Brewer tells WebMD, "For both of us, the disease had already spread by the time it was detected. But we have both responded well to treatment and are disease free, and are praying we stay that way."
Even if the unthinkable happens and testicular cancer returns for Brewer or Armstrong, there is still a better than 50% cure rate for recurrent disease, according to a paper published in the current issue of the Journal of Clinical Oncology.
"For patients who come to me for the first time and require chemotherapy to treat their disease, I tell them that there will be certain problems associated with their therapy, but life will quickly go back to normal," Lawrence Einhorn, MD, tells WebMD. "But even for patients who relapse I can look them in the eye and say with a great deal of confidence even though you weren't cured the first time we still have over a 50% chance we'll cure you this time." Einhorn is Distinguished Professor in the department of medicine, Indiana University Medical Center in Indianapolis, and the study's senior author.
Einhorn and colleagues reviewed the records of more than 60 men treated for recurrent testicular cancer with therapy using high-dose chemotherapy and bone marrow transplantation. "This approach is possible in testicular cancer because we can escalate the dosage of the drugs we use by five or six times the dosage normally given and see something significant," Einhorn says. "This is not possible with drugs used for other solid tumors, such as breast cancer."